Findings of Research Misconduct, 57739 [2018-25065]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 222 / Friday, November 16, 2018 / Notices
HRSA specifically requests comments
on: (1) The necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions; (2) the accuracy of the
estimated burden; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4) the
use of automated collection techniques
or other forms of information
technology to minimize the information
collection burden.
Amy P. McNulty,
Acting Director, Division of the Executive
Secretariat.
[FR Doc. 2018–25070 Filed 11–15–18; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Notice is hereby given that on
October 22, 2018, the U.S. Department
of Health and Human Services (HHS)
Debarring Official, on behalf of the
Secretary of HHS, issued a final notice
of debarment based on an
Administrative Law Judge’s finding of
research misconduct against Rakesh
Srivastava, Ph.D., former Eminent
Scholar and Professor, University of
Kansas Medical Center (KUMC). Dr.
Srivastava engaged in research
misconduct in research proposed or
reported in grant application 1 R01
CA175776–01, submitted to the
National Cancer Institute (NCI),
National Institutes of Health (NIH), on
June 5, 2012. The administrative
actions, including two (2) years of
debarment, were implemented
beginning on October 22, 2018, and are
detailed below.
FOR FURTHER INFORMATION CONTACT:
Wanda K. Jones, Dr. P.H., Interim
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8200.
SUPPLEMENTARY INFORMATION:
Rakesh Srivastava, Ph.D., University
of Kansas Medical Center: Based on the
evidence and findings of an
investigation conducted by KUMC and
additional information obtained by the
Office of Research Integrity (ORI) during
its oversight review, ORI found by a
preponderance of the evidence that Dr.
Rakesh Srivastava (Respondent), former
Eminent Scholar and Professor, KUMC,
intentionally and knowingly submitted
extensive plagiarized text in grant
amozie on DSK3GDR082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:19 Nov 15, 2018
Jkt 247001
application 1 R01 CA175776–01,
‘‘Regulation of Mitochondrial
Metabolism by SIRT4,’’ submitted to
NCI, NIH, to obtain U.S. Public Health
Service (PHS) funds. Specifically, ORI
found that the Respondent intentionally
and knowingly plagiarized scientifically
significant text from the Specific Aims
and Research Strategy sections of a grant
application under review at NIH into his
own grant application, 1 R01
CA175776–01, submitted to NIH eight
months later. Significant text was
included in Respondent’s grant
application, with plagiarized text
accounting for 40% of the Specific Aims
and 50% of the Research Strategy
sections.
ORI issued a charge letter making a
finding of research misconduct and
proposing HHS administrative actions.
Dr. Srivastava subsequently requested a
hearing before an Administrative Law
Judge (ALJ) of the Departmental Appeals
Board to dispute the finding. ORI moved
for summary judgment. On September 5,
2018, the ALJ granted summary
judgment in favor of ORI and issued his
recommended decision, finding that
Respondent intentionally committed
research misconduct by submitting to
NIH a grant application that included
plagiarized words, which included
significant text from another principal
investigator’s grant application that was
contained in the Specific Aims and
Research Strategy sections of the
Respondent’s grant application without
attribution to the other principal
investigator. The ALJ held that
appropriate administrative actions
included a two-year debarment from
any contracting or subcontracting with
any agency of the United States
Government and from eligibility for or
involvement in nonprocurement
programs of the United States
Government referred to as ‘‘covered
transactions.’’ 2 CFR parts 180 and 376.
The ALJ held that it was an appropriate
administrative action to also impose a
two-year prohibition from serving in
any capacity to PHS including, but not
limited to, service on any PHS advisory
committee, board, or peer review
committee, or as a consultant. Under the
regulation, the ALJ’s recommended
decision went to the Assistant Secretary
for Health, who did not modify it and
forwarded it to the HHS Debarring
Official, who is the deciding official for
the debarment. The ALJ decision
constituted the findings of fact to the
HHS Debarring Official in accordance
with 2 CFR 180.845(c). On October 22,
2018, the HHS Debarring Official issued
a final notice of debarment to begin on
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
57739
October 22, 2018, and end on October
21, 2020.
Thus, the research misconduct
finding set forth above became effective,
and the following administrative actions
have been implemented for a period of
two (2) years, beginning on October 22,
2018:
(1) Dr. Srivastava is debarred from any
contracting or subcontracting with any
agency of the United States Government
and from eligibility or involvement in
nonprocurement programs of the United
States Government referred to as
‘‘covered transactions’’ pursuant to
HHS’ Implementation (2 CFR part 376)
of Office of Management and Budget
(OMB) Guidelines to Agencies on
Governmentwide Debarment and
Suspension (2 CFR part 180); and
(2) Dr. Srivastava is prohibited from
serving in any advisory capacity to PHS
including, but not limited to, service on
any PHS advisory committee, board,
and/or peer review committee, or as a
consultant.
Wanda K. Jones,
Interim Director, Office of Research Integrity.
[FR Doc. 2018–25065 Filed 11–15–18; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Solicitation of Nominations for
Appointment to the Tick-Borne
Disease Working Group
Office of HIV/AIDS and
Infectious Disease Policy, Office of the
Assistant Secretary for Health, Office of
the Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
This notice will serve to
announce that the U.S. Department of
Health and Human Services (HHS) is
seeking nominations of non-federal
individuals who represent diverse
scientific disciplines and views and are
interested in being considered for
appointment to the Tick-Borne Disease
Working Group (Working Group).
Resumes or curricula vitae from
qualified individuals who wish to be
considered for appointment as a
member of the Working Group are
currently being accepted.
DATES: Nominations must be received
no later than 5:00 p.m. EST, on
December 14, 2018.
ADDRESSES: All nominations should be
sent to the Tick-Borne Disease Working
Group email address at
tickbornedisease@hhs.gov. Alternately,
nominations can be sent by mail to:
SUMMARY:
E:\FR\FM\16NON1.SGM
16NON1
]]>Agencies
[Federal Register Volume 83, Number 222 (Friday, November 16, 2018)]
[Notices]
[Page 57739]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-25065]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that on October 22, 2018, the U.S.
Department of Health and Human Services (HHS) Debarring Official, on
behalf of the Secretary of HHS, issued a final notice of debarment
based on an Administrative Law Judge's finding of research misconduct
against Rakesh Srivastava, Ph.D., former Eminent Scholar and Professor,
University of Kansas Medical Center (KUMC). Dr. Srivastava engaged in
research misconduct in research proposed or reported in grant
application 1 R01 CA175776-01, submitted to the National Cancer
Institute (NCI), National Institutes of Health (NIH), on June 5, 2012.
The administrative actions, including two (2) years of debarment, were
implemented beginning on October 22, 2018, and are detailed below.
FOR FURTHER INFORMATION CONTACT: Wanda K. Jones, Dr. P.H., Interim
Director, Office of Research Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (240) 453-8200.
SUPPLEMENTARY INFORMATION:
Rakesh Srivastava, Ph.D., University of Kansas Medical Center:
Based on the evidence and findings of an investigation conducted by
KUMC and additional information obtained by the Office of Research
Integrity (ORI) during its oversight review, ORI found by a
preponderance of the evidence that Dr. Rakesh Srivastava (Respondent),
former Eminent Scholar and Professor, KUMC, intentionally and knowingly
submitted extensive plagiarized text in grant application 1 R01
CA175776-01, ``Regulation of Mitochondrial Metabolism by SIRT4,''
submitted to NCI, NIH, to obtain U.S. Public Health Service (PHS)
funds. Specifically, ORI found that the Respondent intentionally and
knowingly plagiarized scientifically significant text from the Specific
Aims and Research Strategy sections of a grant application under review
at NIH into his own grant application, 1 R01 CA175776-01, submitted to
NIH eight months later. Significant text was included in Respondent's
grant application, with plagiarized text accounting for 40% of the
Specific Aims and 50% of the Research Strategy sections.
ORI issued a charge letter making a finding of research misconduct
and proposing HHS administrative actions. Dr. Srivastava subsequently
requested a hearing before an Administrative Law Judge (ALJ) of the
Departmental Appeals Board to dispute the finding. ORI moved for
summary judgment. On September 5, 2018, the ALJ granted summary
judgment in favor of ORI and issued his recommended decision, finding
that Respondent intentionally committed research misconduct by
submitting to NIH a grant application that included plagiarized words,
which included significant text from another principal investigator's
grant application that was contained in the Specific Aims and Research
Strategy sections of the Respondent's grant application without
attribution to the other principal investigator. The ALJ held that
appropriate administrative actions included a two-year debarment from
any contracting or subcontracting with any agency of the United States
Government and from eligibility for or involvement in nonprocurement
programs of the United States Government referred to as ``covered
transactions.'' 2 CFR parts 180 and 376. The ALJ held that it was an
appropriate administrative action to also impose a two-year prohibition
from serving in any capacity to PHS including, but not limited to,
service on any PHS advisory committee, board, or peer review committee,
or as a consultant. Under the regulation, the ALJ's recommended
decision went to the Assistant Secretary for Health, who did not modify
it and forwarded it to the HHS Debarring Official, who is the deciding
official for the debarment. The ALJ decision constituted the findings
of fact to the HHS Debarring Official in accordance with 2 CFR
180.845(c). On October 22, 2018, the HHS Debarring Official issued a
final notice of debarment to begin on October 22, 2018, and end on
October 21, 2020.
Thus, the research misconduct finding set forth above became
effective, and the following administrative actions have been
implemented for a period of two (2) years, beginning on October 22,
2018:
(1) Dr. Srivastava is debarred from any contracting or
subcontracting with any agency of the United States Government and from
eligibility or involvement in nonprocurement programs of the United
States Government referred to as ``covered transactions'' pursuant to
HHS' Implementation (2 CFR part 376) of Office of Management and Budget
(OMB) Guidelines to Agencies on Governmentwide Debarment and Suspension
(2 CFR part 180); and
(2) Dr. Srivastava is prohibited from serving in any advisory
capacity to PHS including, but not limited to, service on any PHS
advisory committee, board, and/or peer review committee, or as a
consultant.
Wanda K. Jones,
Interim Director, Office of Research Integrity.
[FR Doc. 2018-25065 Filed 11-15-18; 8:45 am]
BILLING CODE 4150-31-P
